{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:31:02Z","timestamp":1787841062589,"version":"build-2784847793"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,21]],"date-time":"2014-01-21T00:00:00Z","timestamp":1390262400000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND AND OBJECTIVES:<\/jats:title>\n                    <jats:p>Despite the use of targeted therapy, chronic myelogenous leukemia (CML) currently remains incurable with drug therapy, with patients requiring life-long treatment. Developing either a vaccine to prevent the disease or another novel drug to specifically target and eradicate the CML cell will require the identification of CML-associated cell-surface markers and molecules that can bind specifically to the cell surface. In an attempt to discover peptides that bind specifically to cells in the early chronic phase of the disease, we used phage-display technology to identify heptapeptides that bind specifically to the surface of BCR\/ABL-expressing fibroblasts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>\n                      An\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      system using NIH3T3 stably transfected with pGD210 (BCR\/ABL) was used as a model for the chronic phase of the disease. The cells were panned using a linear heptapeptide phage library (Ph.D 7.0) in a negative\/positive panning strategy with NIH3T3 containing only the plasmid vector as the wild type control.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>We identified four novel peptides that were enriched through this technique. These peptides contained either multiple proline residues or serine\/threonine-proline pairs and showed a confirmed binding preference for BCR\/ABL+ fibroblasts. The peptide Y-R-A-P-W-P-P also showed a binding affinity for granulocytes from untreated CML patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>We have identified several novel peptides that can be used in future studies to identify specific CML cell-surface antigens or provide a novel drug-delivery mechanism.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2014.01.001","type":"journal-article","created":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T15:32:05Z","timestamp":1390836725000},"page":"32-40","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Serine and proline-rich ligands enriched via phage-display technology show preferential binding to BCR\/ABL expressing cells"],"prefix":"10.4103","volume":"7","author":[{"given":"Karen","family":"Shires","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Shankland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheen","family":"Mowla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Njikan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai","family":"Jaymacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"2 Suppl. 2","key":"10.1016\/j.hemonc.2014.01.001_b0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/shem.2003.50045","article-title":"Cytogenetic and molecular mechanisms of resistance to imatinib","volume":"40","author":"Hochhaus","year":"2003","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1016\/j.hemonc.2014.01.001_b0010","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ccr.2009.08.012","article-title":"Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way","volume":"16","author":"Strout","year":"2009","journal-title":"Cancer Cell"},{"issue":"9460","key":"10.1016\/j.hemonc.2014.01.001_b0015","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)70931-4","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.hemonc.2014.01.001_b0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.COT.0000294560.17398.4a","article-title":"CML vaccine induces immune response, preliminary data encouraging","volume":"28","author":"Goodman","year":"2006","journal-title":"Oncol Times"},{"issue":"1","key":"10.1016\/j.hemonc.2014.01.001_b0025","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-09-2046","article-title":"K562\/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate","volume":"16","author":"Smith","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hemonc.2014.01.001_b0030","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1182\/blood-2010-05-282921","article-title":"Targeting neuropilin-1 in human leukemia and lymphoma","volume":"117","author":"Karjalainen","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hemonc.2014.01.001_b0035","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1182\/blood.V98.10.2887","article-title":"Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein","volume":"98","author":"Clark","year":"2001","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hemonc.2014.01.001_b0040","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI488","article-title":"Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia","volume":"101","author":"Yotnda","year":"1998","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.hemonc.2014.01.001_b0045","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1158\/0008-5472.CAN-05-2868","article-title":"BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia","volume":"66","author":"Gr\u00fcnebach","year":"2006","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.hemonc.2014.01.001_b0050","first-page":"57","article-title":"Identification of gene expression signatures for molecular classification in human leukemia cells","volume":"29","author":"Song","year":"2006","journal-title":"Int J Oncol"},{"issue":"11","key":"10.1016\/j.hemonc.2014.01.001_b0055","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1038\/sj.leu.2402732","article-title":"Frequent expression of HAGE in presentation chronic myeloid leukaemias","volume":"16","author":"Adams","year":"2002","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hemonc.2014.01.001_b0060","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/sj.cgt.7700476","article-title":"Tumor cell-targeting by phage-display peptides","volume":"9","author":"Rasmussen","year":"2002","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"10.1016\/j.hemonc.2014.01.001_b0065","first-page":"301","article-title":"Selection and identification of mimic epitopes for gastric cancer-associated antigen MG7 Ag","volume":"2","author":"Xu","year":"2003","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.hemonc.2014.01.001_b0070","first-page":"465","article-title":"Peptide mimotopes of oncoproteins as therapeutic agents in breast cancer","volume":"11","author":"Ashok","year":"2003","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.hemonc.2014.01.001_b0075","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-8722-1-8","article-title":"Isolation of specific and biologically active peptides that bind cells from patients with acute myeloid leukemia (AML)","volume":"1","author":"Galili","year":"2008","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.hemonc.2014.01.001_b0080","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1517\/13543784.2011.632407","article-title":"Identification of heptapeptides interacting with IFN-\u03b1-sensitive CML cells","volume":"20","author":"Liu","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"10.1016\/j.hemonc.2014.01.001_b0085","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood.V97.8.2406","article-title":"A model of human p210(bcr\/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR\/ABL-containing retroviral vector","volume":"97","author":"Zhao","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hemonc.2014.01.001_b0090","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1128\/MCB.15.3.1286","article-title":"The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation","volume":"15","author":"Renshaw","year":"1995","journal-title":"Mol Cell Biol"},{"issue":"10","key":"10.1016\/j.hemonc.2014.01.001_b0095","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1074\/jbc.270.10.5039","article-title":"Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR\/ABL","volume":"270","author":"Salgia","year":"1995","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.hemonc.2014.01.001_b0100","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/cncr.10670","article-title":"Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells","volume":"95","author":"Cheng","year":"2002","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.hemonc.2014.01.001_b0105","doi-asserted-by":"crossref","first-page":"10289","DOI":"10.1128\/MCB.24.23.10289-10299.2004","article-title":"Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release","volume":"24","author":"Deming","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"4944","key":"10.1016\/j.hemonc.2014.01.001_b0110","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.hemonc.2014.01.001_b0115","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia \u2013 a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.hemonc.2014.01.001_b0120","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukemia","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hemonc.2014.01.001_b0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.blre.2005.01.008","article-title":"Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukemia","volume":"20","author":"Hughes","year":"2006","journal-title":"Blood Rev"},{"issue":"1\u20132","key":"10.1016\/j.hemonc.2014.01.001_b0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jim.2004.05.004","article-title":"Isolation of human prostate cancer cell reactive antibodies using phage display technology","volume":"291","author":"Popkov","year":"2004","journal-title":"J Immunol Methods"},{"issue":"4","key":"10.1016\/j.hemonc.2014.01.001_b0135","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1128\/MCB.20.4.1149-1161.2000","article-title":"Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder","volume":"20","author":"Hao","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"15","key":"10.1016\/j.hemonc.2014.01.001_b0140","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/0008-5472.CAN-03-3656","article-title":"Effect of mutational inactivation of tyrosine kinase activity on BCR\/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors","volume":"64","author":"Ramaraj","year":"2004","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.hemonc.2014.01.001_b0145","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1038\/sj.onc.1210979","article-title":"BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor","volume":"27","author":"Tao","year":"2008","journal-title":"Oncogene"},{"issue":"6128","key":"10.1016\/j.hemonc.2014.01.001_b0150","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/328342a0","article-title":"Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia","volume":"328","author":"Gordon","year":"1987","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.hemonc.2014.01.001_b0155","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1172\/JCI115985","article-title":"Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV","volume":"90","author":"Verfaillie","year":"1992","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.hemonc.2014.01.001_b0160","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1172\/JCI118820","article-title":"BCR\/ABL expression stimulates integrin function in hematopoietic cell lines","volume":"98","author":"Bazzoni","year":"1996","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.hemonc.2014.01.001_b0165","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1172\/JCI119520","article-title":"BCR\/ABL induces multiple abnormalities of cytoskeletal function","volume":"100","author":"Salgia","year":"1997","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.hemonc.2014.01.001_b0170","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2003-01-0062","article-title":"Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development","volume":"102","author":"Wertheim","year":"2003","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hemonc.2014.01.001_b0175","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1002\/j.1460-2075.1994.tb06897.x","article-title":"Identification of Src, Fyn, Lyn, P13K and Abl SH3 domain ligands using phage display libraries","volume":"13","author":"Rickles","year":"1994","journal-title":"EMBO J"},{"issue":"2","key":"10.1016\/j.hemonc.2014.01.001_b0180","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1096\/fasebj.14.2.231","article-title":"The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains","volume":"14","author":"Kay","year":"2000","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.hemonc.2014.01.001_b0185","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0962-8924(02)02253-5","article-title":"Pinning down proline-directed phosphorylation signaling","volume":"12","author":"Lu","year":"2002","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.hemonc.2014.01.001_b0190","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.biophys.33.110502.133346","article-title":"The use of in vitro peptide-library screens in the analysis of phosphoserine\/threonine-binding domain structure and function","volume":"33","author":"Yaffe","year":"2004","journal-title":"Annu Rev Biophys Biomol Struct"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387614000028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387614000028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201407010-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:41:00Z","timestamp":1787838060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201407010-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2014.01.001","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}